Preferences help
enabled [disable] Abstract
Number of results
2016 | 6 | 1 | A18-23
Article title

Imaging for Cardiotoxicity: Many Issues, Many Questions

Title variants
Languages of publication
Physical description
  • 1. Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30(31): 3792-3799.
  • 2. Wang L, Tan TC, Halpern EF et al. Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline- Based Chemotherapy. Am J Cardiol 2015; 116(3): 442-446.
  • 3. Dorosz JL, Lezotte DC, Weitzenkamp DA et al. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012; 59(20): 1799-1808.
  • 4. Walker J, Bhullar N, Fallah-Rad N et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010; 28(21): 3429-3436.
  • 5. Thavendiranathan P, Grant AD, Negishi T et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013; 61(1): 77-84.
  • 6. Cardinale D, Colombo A, Bacchiani G et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131(22): 1981-1988.
  • 7. Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55(3): 213-220.
  • 8. Ewer MS, Ali MK, Mackay B et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984; 2(2): 112-117.
  • 9. Mousavi N, Tan TC, Ali M et al. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015; 16(9): 977- -984.
  • 10. Sawaya H, Sebag IA, Plana JC et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011; 107(9): 1375-1380.
  • 11. Negishi K, Negishi T, Hare JL et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013; 26(5): 493-498.
  • 12. Thavendiranathan P, Poulin F, Lim KD et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014; 63(25 Pt A): 2751-2768.
  • 13. Ho E, Brown A, Barrett P et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart 2010; 96(9): 701-707.
  • 14. Cheung YF, Hong WJ, Chan GC et al. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy. Heart 2010; 96(14): 1137-1141.
  • 15. Negishi K, Negishi T, Haluska BA et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014; 15(3): 324-331.
  • 16. Ambale-Venkatesh B, Lima JA. Cardiac MRI: a central prognostic tool in myocardial fibrosis. Nat Rev Cardiol 2015; 12(1): 18-29.
  • 17. Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol 2013; 111(5): 717-722.
  • 18. Toro-Salazar OH, Gillan E, O’Loughlin MT, Burke GS et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 2013; 6(6): 873-880.
  • 19. Armstrong GT, Plana JC, Zhang N et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30(23): 2876-2884.
  • 20. Neilan TG, Coelho-Filho OR, Pena-Herrera D et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 2012; 110(11): 1679-1686.
  • 21. Drafts BC, Twomley KM, D’Agostino R Jr. et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6(8): 877-885.
  • 22. Francis SA, Cheng S, Arteaga CL, Moslehi J. Heart failure and breast cancer therapies: moving towards personalized risk assessment. J Am Heart Assoc 2014; 3(1): e000780.
  • 23. Hole T, Otterstad JE, St John Sutton M et al. Differences between echocardiographic measurements of left ventricular dimensions and function by local investigators and a core laboratory in a 2-year follow-up study of patients with an acute myocardial infarction. Eur J Echocardiogr 2002; 3(4): 263-270.
  • 24. Chung ES, Leon AR, Tavazzi L et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117(20): 2608-2616.
  • 25. Foster E, Wasserman HS, Gray W et al. Quantitative assessment of severity of mitral regurgitation by serial echocardiography in a multicenter clinical trial of percutaneous mitral valve repair. Am J Cardiol 2007; 100(10): 1577-1583.
  • 26. Douglas PS, DeCara JM, Devereux RB et al. American Society of Echocardiography Standards; American College of Cardiology Foundation. Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation. J Am Soc Echocardiogr 2009; 22(7): 755-765.
  • 27. Acker MA, Bolling S, Shemin R, Kirklin J et al. Acorn Trial Principal Investigators and Study Coordinators. Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. J Thorac Cardiovasc Surg 2006; 132(3): 568-577, 577.e1-4.
  • 28. Douglas PS, Waugh RA, Bloomfield G et al. Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trial. J Am Soc Echocardiogr 2013; 26(4): 348-358.e3.
  • 29. Oh JK, Pellikka PA, Panza JA et al. STICH Trial Investigators. Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. J Am Soc Echocardiogr. 2012; 25(3): 327-336.
  • 30. Panza JA, Velazquez EJ, She L et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected]. J Am Coll Cardiol 2014; 64(6): 553-561.
  • 31. Gierada DS, Garg K, Nath H et al. CT quality assurance in the lung screening study component of the National Lung Screening Trial: implications for multicenter imaging trials. AJR Am J Roentgenol 2009; 193(2): 419-424.
  • 32. Daubert MA, Yow E, Barnhart HX et al. Quality Improvement Implementation: Improving Reproducibility in the Echocardiography Laboratory. J Am Soc Echocardiogr 2015; 28(8): 959-968.
  • 33. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 2014; 3(1): e000472.
  • 34. Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014; 15(10): 1063-1093.
  • 35. Advani PP, Ballman KV, Dockter TJ et al. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol 2016; 34(6): 581-587.
  • 36. Morris PG, Dickler M, McArthur HL et al. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent shortterm changes in left ventricular ejection fraction. J Clin Oncol 2009; 27(36): 6117-6123.
  • 37. Chavez-MacGregor M, Niu J, Zhang N et al. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer. J Clin Oncol 2015; 33(19): 2176-2183.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.